← Patent-cliff monitor small molecule VYXEOS CYTARABINE; DAUNORUBICIN
Loss of exclusivity April 2033 latest FDA-listed patent expiry
Drug detail Brand name VYXEOS Active ingredient CYTARABINE; DAUNORUBICIN Strength 100MG;44MG Dosage form POWDER Route INTRAVENOUS Modality Small molecule FDA approval August 2017 Marketing status RX
Listed patents Patent Expires Type 10166184*PED April 2033 — 10028912*PED April 2033 — 10835492*PED April 2033 — 10166184 October 2032 product 10835492 October 2032 use U-3150 10028912 October 2032 product 8092828*PED October 2029 — 8092828 April 2029 use U-3147 8022279*PED March 2028 — 8022279 September 2027 product 7850990*PED July 2027 — 9271931*PED July 2027 — 9271931 January 2027 product 7850990 January 2027 product 8518437 June 2026 product
Regulatory exclusivity Code Expires PED September 2028 ODE-350 March 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.